48
Participants
Start Date
August 3, 2017
Primary Completion Date
December 21, 2017
Study Completion Date
December 21, 2017
APL-130277
APL-130277 single dose
Placebo
Placebo single dose
Moxifloxacin
moxifloxacin 400mg single dose
Atlanta Center for Medical Research, Atlanta
Bioclinica Reserach, Orlando
MD Clinical, Hallandale
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
Casa di Cura villa Margherita (Neurologia), Arcugnano
QUEST Research Institute, Farmington Hills
The NeuroMedical Center, PC, Baton Rouge
Clinical Trials, Inc., Little Rock
Central Texas Neurology Consultants, Round Rock
Movement Disorders Center of Arizona, Scottsdale
The Parkinson's and Movement Disorder Institute, Fountain Valley
Centro Ricerche San Raffaele, Cassino
Agine Research Center, University Foundahon Chica-Pescara, Behavioral Neurology and Movement Disorders Unit, Chieti
Neurologia, Policlinico Tor Vergata, Rome
IRCCS San Raffaele Pisana,Clinical Trial Center, Rome
Sumitomo Pharma America, Inc.
INDUSTRY